Long-Term Safety of Ospemifene 60 mg Oral Daily Dose for the Treatment of Vulvar and Vaginal Atrophy (VVA) in Postmenopausal Women Without a Uterus

Exclusion Criteria

• •Had completed Protocol 15-50310 without any clinically significant abnormal findings at the end-of-study visit for Protocol 15-50310
• •Provided written informed consent to participate in the study and agreed to follow dosing instructions and complete all required study visits
• •Had clinically significant abnormal findings at the Week 12 End of Study visit for Protocol 15-50310
• •Had any physical or mental condition which, in the opinion of the investigator, may have interfered with the subject's ability to comply with the study procedures